<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690313</url>
  </required_header>
  <id_info>
    <org_study_id>Vig508</org_study_id>
    <nct_id>NCT00690313</nct_id>
  </id_info>
  <brief_title>Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections</brief_title>
  <official_title>To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illinois Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Illinois Retina Associates</source>
  <brief_summary>
    <textblock>
      Antibiotic eye drops are being used before and after intravitreal injections. Currently there
      is no study indicating the benefit of there usage or their dosage.

      In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior
      to the injection versus 1 day prior to intravitreal injection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timed study</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Intravitreal Injection Patients</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigamox</intervention_name>
    <description>eye drops 3 times day either 1 or 3 days prior to intravitreal injection</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who need intravitreal injections patients who are willing to participate in
             the study

        Exclusion Criteria:

          -  Patients who are allergic to Vigamox or who have taken any eye drops within the past 3
             weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kourous A Rezaei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Illinois Retina Associates SC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kourous A Rezaei, MD</last_name>
    <phone>708-596-8710</phone>
    <email>karezaei@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David J Baczewski</last_name>
    <phone>708-915-6808</phone>
    <email>davidb@illinoisretina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David J Baczewski</last_name>
      <phone>708-915-6808</phone>
      <email>davidb@illinoisretina.com</email>
    </contact>
    <investigator>
      <last_name>Kourous A Rezaei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>June 3, 2008</last_update_submitted>
  <last_update_submitted_qc>June 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kourous Rezaei MD</name_title>
    <organization>Illinois Retina Associates SC</organization>
  </responsible_party>
  <keyword>Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

